Corvus Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
CRVS$11.35+7.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · September 30, · · December 31, | ||||||
| · 2025 · 2024 | ||||||
| Assets · · | ||||||
| Current assets: · · | ||||||
| Cash and cash equivalents | | $2,867 | | $8,740 | ||
| Marketable securities | | 62,822 | | 43,224 | ||
| Accounts receivable - related party | | 32 | | 75 | ||
| Prepaid and other current assets | | 1,223 | | 2,368 | ||
| Total current assets | | 66,944 | | 54,407 | ||
| Property and equipment, net | | 221 | | 151 | ||
| Operating lease right-of-use asset | | | 927 | | | 1,177 |
| Investment in Angel Pharmaceuticals | | | 11,530 | | | 12,540 |
| Other assets | | | 852 | | | 632 |
| Total assets | | $80,474 | | $68,907 | ||
| | | | | | | |
| Liabilities and Stockholders’ Equity | | | | |||
| Current liabilities: | | | ||||
| Accounts payable | | $1,974 | | $2,582 | ||
| Operating lease liability | | | 379 | | | 185 |
| Accrued and other liabilities | | 5,721 | | 3,725 | ||
| Warrant liability | | | — | | | 28,910 |
| Total current liabilities | | 8,074 | | 35,402 | ||
| Operating lease liability | | | 632 | | | 937 |
| Total liabilities | | 8,706 | | 36,339 | ||
| Commitments and contingencies (Note 15) | | | ||||
| Stockholders’ equity: | | | ||||
| Preferred stock: $0.0001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; 0 shares issued and outstanding at each of September 30, 2025 and December 31, 2024 | | | — | | | — |
| Common stock: $0.0001 par value; 290,000,000 shares authorized at September 30, 2025 and December 31, 2024; 74,681,872 and 67,899,779 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | | 7 | | 7 | ||
| Additional paid-in capital | | 472,793 | | 430,859 | ||
| Accumulated other comprehensive loss | | (1,060) | | (1,288) | ||
| Accumulated deficit | | (399,972) | | (397,010) | ||
| Total stockholders’ equity | | 71,768 | | 32,568 | ||
| Total liabilities and stockholders’ equity | | $80,474 | | $68,907 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.